Nicotinic acetylcholine receptor variation and response to smoking cessation therapies

Pharmacogenetics and Genomics

Volumn 23, Issue 2, 2013, Pages 94-103

  Bergen, Andrew W ^a   Javitz, Harold S ^a   Krasnow, Ruth ^a   Nishita, Denise ^a   Michel, Martha ^a   Conti, David V ^b   Liu, Jinghua ^b   Lee, Won ^b   Edlund, Christopher K ^b   Hall, Sharon ^c   Kwok, Pui Yan ^d   Benowitz, Neal L ^c   Baker, Timothy B ^e   Tyndale, Rachel F ^f   Lerman, Caryn ^g   Swan, Gary E ^a  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

logistic regression; mediation analysis; nicotine dependence; nicotinic acetylcholine receptor variation; pharmacotherapy; randomized clinical trials

Indexed keywords

AMFEBUTAMONE; NICOTINIC RECEPTOR; PLACEBO; VARENICLINE;

ARTICLE; BEHAVIOR THERAPY; CONTROLLED STUDY; ETHNICITY; FEMALE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; PERSONALIZED MEDICINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION PROGRAM; TOBACCO DEPENDENCE; TREATMENT OUTCOME;

EID: 84873088298     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32835cdabd     Document Type: Article

References (82)

1. Rostron B. Smoking-attributable mortality in the United States. Epidemiology 2011; 22:350-355.
2. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003; 362:847-852.
3. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and dependence: 2008 update US Public Health Service Clinical Practice Guideline executive summary. Respir Care 2008; 53:1217-1222.
4. Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob Res 2008; 10:1245-1250.
5. Baker TB, Piper ME, McCarthy DE, Bolt DM, Smith SS, Kim SY, et al. Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. Nicotine Tob Res 2007; 9 (Suppl 4):S555-S570.
6. Fagerström K, Russ C, Yu CR, Yunis C, Foulds J. The Fagerström test for nicotine dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. Nicotine Tob Res 2012; 14:1467-1473.
7. Brown RA, Niaura R, Lloyd-Richardson EE, Strong DR, Kahler CW, Abrantes AM, et al. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine Tob Res 2007; 9:721-730.
8. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 2006; 79:600-608.
9. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, et al. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 2008; 65:683-693.
10. Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Mol Med 2010; 16:247-253.
11. Ockene JK, Emmons KM, Mermelstein RJ, Perkins KA, Bonollo DS, Voorhees CC, et al. Relapse and maintenance issues for smoking cessation. Health Psychol 2000; 19:17-31.
12. Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008; 84:320-325.
13. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav 2009; 92:6-11.
14. Loh WY, Piper ME, Schlam TR, Fiore MC, Smith SS, Jorenby DE, et al. Should all smokers use combination smoking cessation pharmacotherapy? Using novel analytic methods to detect differential treatment effects over 8 weeks of pharmacotherapy. Nicotine Tob Res 2011; 14:131-141.
15. Li MD, Beuten J, Ma JZ, Payne TJ, Lou XY, Garcia V, et al. Ethnic-and gender-specific association of the nicotinic acetylcholine receptor alpha4 subunit gene (CHRNA4) with nicotine dependence. Hum Mol Genet 2005; 14:1211-1219.
16. Greenbaum L, Kanyas K, Karni O, Merbl Y, Olender T, Horowitz A, et al. Why do young women smoke? I. Direct and interactive effects of environment, psychological characteristics and nicotinic cholinergic receptor genes. Mol Psychiatry 2006; 11:312-322, 223.
17. Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF, et al. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 2007; 16:24-35.
18. Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 2007; 16:36-49.
19. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008; 452:638-642.
20. Berrettini W, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H, et al. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry 2008; 13:368-373.
21. Stevens VL, Bierut LJ, Talbot JT, Wang JC, Sun J, Hinrichs AL, et al. Nicotinic receptor gene variants influence susceptibility to heavy smoking. Cancer Epidemiol Biomarkers Prev 2008; 17:3517-3525.
22. Weiss RB, Baker TB, Cannon DS, von Niederhausern A, Dunn DM, Matsunami N, et al. A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. PLoS Genet 2008; 4:e1000125.
23. Baker TB, Weiss RB, Bolt D, von Niederhausern A, Fiore MC, Dunn DM, et al. Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. Nicotine Tob Res 2009; 11:785-796.
24. Caporaso N, Gu F, Chatterjee N, Sheng-Chih J, Yu K, Yeager M, et al. Genome-wide and candidate gene association study of cigarette smoking behaviors. PLoS One 2009; 4:e4653.
25. Chen X, Chen J, Williamson VS, An SS, Hettema JM, Aggen SH, et al. Variants in nicotinic acetylcholine receptors alpha5 and alpha3 increase risks to nicotine dependence. Am J Med Genet B Neuropsychiatr Genet 2009; 150B:926-933.
26. Hong LE, Hodgkinson CA, Yang Y, Sampath H, Ross TJ, Buchholz B, et al. A genetically modulated, intrinsic cingulate circuit supports human nicotine addiction. Proc Natl Acad Sci USA 2010; 107:13509-13514.
27. Saccone NL, Wang JC, Breslau N, Johnson EO, Hatsukami D, Saccone SF, et al. The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans. Cancer Res 2009; 69:6848-6856.
28. Furberg H, Kim Y, Dackor J, Boerwinkle E, Franceschini N, Ardissino D, et al. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet 2010; 42:441-447.
29. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet 2010; 42:436-440.
30. Saccone NL, Culverhouse RC, Schwantes-An TH, Cannon DS, Chen X, Cichon S, et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet 2010; 6:pii: e1001053.
31. Li MD, Xu Q, Lou XY, Payne TJ, Niu T, Ma JZ. Association and interaction analysis of variants in CHRNA5/CHRNA3/CHRNB4 gene cluster with nicotine dependence in African and European Americans. Am J Med Genet B Neuropsychiatr Genet 2010; 153B:745-756.
32. Li MD, Yoon D, Lee JY, Han BG, Niu T, Payne TJ, et al. Associations of variants in CHRNA5/A3/B4 gene cluster with smoking behaviors in a Korean population. PLoS One 2010; 5:e12183.
33. Saccone NL, Schwantes-An TH, Wang JC, Grucza RA, Breslau N, Hatsukami D, et al. Multiple cholinergic nicotinic receptor genes affect nicotine dependence risk in African and European Americans. Genes Brain Behav 2010; 9:741-750.
34. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet 2010; 42:448-453.
35. Wessel J, McDonald SM, Hinds DA, Stokowski RP, Javitz HS, Kennemer M, et al. Resequencing of nicotinic acetylcholine receptor genes and association of common and rare variants with the Fagerström test for nicotine dependence. Neuropsychopharmacology 2010; 35: 2392-2402.
36. Hamidovic A, Kasberger JL, Young TR, Goodloe RJ, Redline S, Buxbaum SG, et al. Genetic variability of smoking persistence in African Americans. Cancer Prev Res (Phila) 2011; 4:729-734.
37. Han S, Yang BZ, Kranzler HR, Oslin D, Anton R, Gelernter J. Association of CHRNA4 polymorphisms with smoking behavior in two populations. Am J Med Genet B Neuropsychiatr Genet 2011; 156B:421-429.
38. Xie P, Kranzler HR, Krauthammer M, Cosgrove KP, Oslin D, Anton RF, et al. Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol Psychiatry 2011; 70: 528-536.
39. Chen LS, Saccone NL, Culverhouse RC, Bracci PM, Chen CH, Dueker N, et al. Smoking and genetic risk variation across populations of European, Asian, and African American ancestry-a meta-analysis of chromosome 15q25. Genet Epidemiol 2012; 36:340-351.
40. David SP, Hamidovic A, Chen GK, Bergen AW, Wessel J, Kasberger JL, et al. Genome-wide meta-analyses of smoking behaviors in African Americans. Transl Psychiatry 2012; 2:e119.
41. Hartz SM, Short SE, Saccone NL, Culverhouse R, Chen L, Schwantes-An TH, et al. Increased genetic vulnerability to smoking at CHRNA5 in early-onset smokers. Arch Gen Psychiatry 2012; 69:854-860.
42. Rice JP, Hartz SM, Agrawal A, Almasy L, Bennett S, Breslau N, et al. CHRNB3 is more strongly associated with Fagerström test for cigarette dependence-based nicotine dependence than cigarettes per day: phenotype definition changes genome-wide association studies results. Addiction 2012; 107:2019-2028.
43. Ehringer MA, Clegg HV, Collins AC, Corley RP, Crowley T, Hewitt JK, et al. Association of the neuronal nicotinic receptor beta2 subunit gene (CHRNB2) with subjective responses to alcohol and nicotine. Am J Med Genet B Neuropsychiatr Genet 2007; 144B:596-604.
44. Hoft NR, Stitzel JA, Hutchison KE, Ehringer MA. CHRNB2 promoter region: association with subjective effects to nicotine and gene expression differences. Genes Brain Behav 2011; 10:176-185.
45. Rigbi A, Yakir A, Sarner-Kanyas K, Pollak Y, Lerer B. Why do young women smoke? VI. A controlled study of nicotine effects on attention: pharmacogenetic interactions. Pharmacogenomics J 2011; 11:45-52.
46. Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD, et al. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet 2008; 17:2834-2848.
47. Heitjan DF, Guo M, Ray R, Wileyto EP, Epstein LH, Lerman C. Identification of pharmacogenetic markers in smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:712-719.
48. Freathy RM, Ring SM, Shields B, Galobardes B, Knight B, Weedon MN, et al. A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy. Hum Mol Genet 2009; 18:2922-2927.
49. King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology 2011; 37:641-650.
50. Munafo MR, Johnstone EC, Walther D, Uhl GR, Murphy MF, Aveyard P. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob Res 2011; 13:982-988.
51. Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Schatzberg AF, et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet 2011; 156B:275-284.
52. Chen LS, Baker TB, Piper ME, Breslau N, Cannon DS, Doheny KF, et al. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. Am J Psychiatry 2012; 169:735-742.
53. Perkins KA, Lerman C, Mercincavage M, Fonte CA, Briski JL. Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch. Cancer Epidemiol Biomarkers Prev 2009; 18:2608-2612.
54. Swan GE, Javitz HS, Jack LM, Wessel J, Michel M, Hinds DA, et al. Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes. Pharmacogenomics J 2011; 12:349-358.
55. Wassenaar CA, Dong Q, Wei Q, Amos CI, Spitz MR, Tyndale RF. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst 2011; 103:1342-1346.
56. Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 2006; 31:231-242.
57. Swan GE, McClure JB, Jack LM, Zbikowski SM, Javitz HS, Catz SL, et al. Behavioral counseling and varenicline treatment for smoking cessation. Am J Prev Med 2010; 38:482-490.
58. Hall SM, Humfleet GL, Gorecki JA, Munoz RF, Reus VI, Prochaska JJ. Older versus younger treatment-seeking smokers: differences in smoking behavior, drug and alcohol use, and psychosocial and physical functioning. Nicotine Tob Res 2008; 10:463-470.
59. Hall SM, Humfleet GL, Munoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. Addiction 2009; 104: 1043-1052.
60. Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, et al. Efficacy of bupropion alone and in combination with nicotine gum. Nicotine Tob Res 2007; 9:947-954.
61. McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC, et al. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. Nicotine Tob Res 2008; 10: 717-729.
62. Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009; 66:1253-1262.
63. Nishita DM, Jack LM, McElroy M, McClure JB, Richards J, Swan GE, et al. Clinical trial participant characteristics and saliva and DNA metrics. BMC Med Res Methodol 2009; 9:71.
64. Thomas PD, Mi H, Swan GE, Lerman C, Benowitz N, Tyndale RF, et al. A systems biology network model for genetic association studies of nicotine addiction and treatment. Pharmacogenet Genomics 2009; 19:538-551.
65. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38:904-909.
66. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007; 39:906-913.
67. Ambler G, Omar RZ, Royston P. A comparison of imputation techniques for handling missing predictor values in a risk model with a binary outcome. Stat Methods Med Res 2007; 16:277-298.
68. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict 1991; 86:1119-1127.
69. Rubin DB. Multiple imputation for nonresponse in surveys. New York: J. Wiley & Sons; 1987.
70. Mackinnon DP, Warsi G, Dwyer JHA. Simulation study of mediated effect measures. Multivariate Behav Res 1995; 30:41.
71. Gauderman WJ, Morrison JM. @@QUANTO: a computer program for power and sample size calculations for genetic-epidemiology studies; 2006. 1.2 ed.
72. MacKinnon DP, Krull JL, Lockwood CM. Equivalence of the mediation, confounding and suppression effect. Prev Sci 2000; 1:173-181.
73. Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ. Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature 2011; 471:597-601.
74. Salas R, Orr-Urtreger A, Broide RS, Beaudet A, Paylor R, De Biasi M. The nicotinic acetylcholine receptor subunit alpha 5 mediates short-term effects of nicotine in vivo. Mol Pharmacol 2003; 63:1059-1066.
75. Jackson KJ, Marks MJ, Vann RE, Chen X, Gamage TF, Warner JA, et al. Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice. J Pharmacol Exp Ther 2010; 334:137-146.
76. Hong LE, Gu H, Yang Y, Ross TJ, Salmeron BJ, Buchholz B, et al. Association of nicotine addiction and nicotine's actions with separate cingulate cortex functional circuits. Arch Gen Psychiatry 2009; 66:431-441.
77. Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X, et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry 2008; 165:1163-1171.
78. Winterer G, Mittelstrass K, Giegling I, Lamina C, Fehr C, Brenner H, et al. Risk gene variants for nicotine dependence in the CHRNA5-CHRNA3-CHRNB4 cluster are associated with cognitive performance. Am J Med Genet B Neuropsychiatr Genet 2010; 153B:1448-1458.
79. Kleykamp BA, Jennings JM, Eissenberg T. Effects of transdermal nicotine and concurrent smoking on cognitive performance in tobacco-abstinent smokers. Exp Clin Psychopharmacol 2011; 19:75-84.
80. Patterson F, Jepson C, Loughead J, Perkins K, Strasser AA, Siegel S, et al. Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend 2010; 106:61-64.
81. Ioannidis JP. Why most discovered true associations are inflated. Epidemiology 2008; 19:640-648.
82. Ioannidis JP. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ 2009; 181:488-493.